Join
Live feed
·
PRReleasevia Quantisnow
Nexentis Technologies Inc. logo

Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases

ByQuantisnow·Wall Street's wire, on your screen.
NXTS· Nexentis Technologies Inc.
Industrials

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NXTS (Nexentis Technologies Inc.) and more on Quantisnow.